Omalizumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant | Catalog C020P.LA

Omalizumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant. Omalizumab biosimilar CHO stable cell line is available for licensing to manufacture the omalizumab protein. The research grade omalizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available.

Product Specifications

Catalog No.	C020P.LA
Product Name	Omalizumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Anti-IgE Humanized Monoclonal Antibody
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 LALAPG Fc Silent Mutant
Source/Host	Produced in the Omalizumab biosimilar CHO stable cell line.
Specificity	Specifically binds to human immunoglobulin E (IgE) free in blood and interstitial fluid, and to membrane-bound form (mIgE) on mIgE-expressing B lymphocytes. Does not bind to IgE already bound by high-affinity receptor (FcεRI).

Properties & Storage

Applications	Functional assay, neutralization, blocking, ELISA.
Formulation	0.2 µM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Omalizumab is a humanized antibody used to reduce sensitivity to inhaled or ingested allergens, especially in the control of moderate to severe allergic asthma which does not respond to high doses of corticosteroids.

Immunoglobulin E (IgE) found in mammals only exists as monomers consisting of two heavy chains (ε chain) and two light chains, with the ε chain containing 4 Ig-like constant domains (Cε1-Cε4). In addition to immunity to parasites, IgE plays an essential role in type I hypersensitivity, which manifests various allergic diseases, and allergic conditions, such as anaphylactic reactions to certain drugs, bee stings, and antigen preparations used in specific desensitization immunotherapy.